RIBAPHARM INC Form SC 13G February 12, 2003

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

Ribapharm Inc.				
(Name of Issuer)				
Common Stock, par value \$.01 per share				
(Title of Class of Securities)				
762537108				
(CUSIP Number)				
December 31, 2002				
(Date of Event Which Requires Filing of this Statement)				

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [] Rule 13d-1(b)
- [] Rule 13d-1(c)
- [x] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 762537108 13G Page 2 of 5 Pages

NAME OF REPORTING PERSON

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
ICN Pharmaceuticals, Inc.

2	CHECK THE APPI [] (a) [] (b)				
3	SEC USE ONLY	SEC USE ONLY			
4	CITIZENSHIP OF Delaware	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 120,100,000		
		6	SHARED VOTING POWER		
		7	SOLE DISPOSITIVE POWER 120,100,000		
		8	SHARED DISPOSITIVE POWER		
9	AGGREGATE AMOU	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 120,100,000			
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
12	TYPE OF REPORTING PERSON CO				

Item 1(a). Name of Issuer.

Ribapharm Inc.

Item 1(b). Address of Issuer's Principal Executive Offices.

3300 Hyland Avenue Costa Mesa, CA 92626

Item 2(a). Name of Person Filing.

ICN Pharmaceuticals, Inc.

Item 2(b). Address of Principal Business Office or, if None, Residence.

3300 Hyland Avenue Costa Mesa, CA 92626

Item 2(c). Citizenship.

Delaware

Item 2(d). Title of Class of Securities.

Common Stock, par value \$.01 per share

Item 2(e). CUSIP Number.

762537108

Not applicable as this Schedule is filed pursuant to Rule 13d-1(d).

Item 4. Ownership.

- (a) Amount beneficially owned: 120,100,000 shares
- (b) Percent of class: 80.1%
- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or direct the vote: 120,100,000 shares
 - (ii) Shared power to vote or direct the vote: -0-
 - (iii) Sole power to dispose or to direct the disposition: 120,100,000 shares
 - (iv) Shared power to dispose or to direct the disposition: $\label{eq:condition} -0-$
- Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 11, 2003

ICN PHARMACEUTICALS, INC.

By: /s/ Gregory Keever

Name: Gregory Keever

Title: Executive Vice President,

General Counsel and Corporate Secretary